Skip to main content
MTEX
NASDAQ Life Sciences

Mannatech Q2 10-Q Reveals Going Concern Doubt and Nasdaq Equity Deficiency

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Household Product Stocks · Consumer
Sentiment info
Negative
Importance info
8
Price
$5.07
Mkt Cap
$9.783M
52W Low
$3.8
52W High
$12.454
52W Position info
33% above low
Off High info
59% below high
Rel. Volume
Market data snapshot near publication time

MTEX sits 33% above its 52-week low of $3.8.

Summary

Mannatech's Q2 10-Q discloses going concern doubt, a Nasdaq equity deficiency, and a cyber incident, despite reporting a $1.0 million quarterly profit.


Key Events · Earnings and Guidance · MTEX

  • Going Concern Doubt

    Management states substantial doubt about the company's ability to continue as a going concern within one year, citing decline in net sales, operating losses, negative cash flows, and an organizational structure no longer aligned with current operating scale.

  • Nasdaq Equity Deficiency

    Company received notice on April 20, 2026 of non-compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity of $2,500,000); submitted a compliance plan on June 4, 2026 and provided additional information on July 14, 2026.

  • Cyber Incident

    During Q2 2026, a cyber incident resulted in potential exposure of personal information of certain independent associates and customers; investigation ongoing, no litigation filed.

  • Cost-Cutting Measures

    Director compensation converted to equity (expected $0.8M annual cash preservation), headcount reductions, and facilities/overhead actions effective March 31, 2026.


Analysis · MTEX · Life Sciences

Mannatech's Q2 10-Q discloses that management has substantial doubt about the company's ability to continue as a going concern within one year, citing declining sales, operating losses, and negative cash flows. The company also remains out of compliance with Nasdaq's minimum stockholders' equity rule, having received a deficiency notice on April 20, 2026 and submitted a compliance plan on June 4, 2026. While the quarter showed a net profit of $1.0 million, the profit was driven largely by a $0.3 million foreign currency gain, and the company's cash position remains tight at $6.0 million. The filing also reveals a cyber incident and cost-cutting measures, including converting director compensation to equity.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTEX was trading at $5.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8M. The 52-week trading range was $3.80 to $12.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTEX - Latest Insights

MTEX
Nov 12, 2026, 4:02 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.98
Real-time Price: $6.30 info
Change: -$2.68 (-30%) info
Market Cap: $12.157M info
MTEX
Nov 12, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $8.82
Real-time Price: $6.30 info
Change: -$2.52 (-29%) info
Market Cap: $12.157M info
MTEX
Oct 20, 2026, 5:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.26
Real-time Price: $6.30 info
Change: -$1.96 (-24%) info
Market Cap: $12.157M info
MTEX
Oct 14, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.25
Real-time Price: $6.30 info
Change: -$0.950 (-13%) info
Market Cap: $12.157M info
MTEX
Aug 12, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.07
Real-time Price: $6.30 info
Change: +$1.23 (+24%) info
Market Cap: $12.157M info